Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 115

Sort by

Sort Order Select

Journal Articles

Efficacy of Venetoclax-Based Therapy Followed By Allogeneic Transplantation in Newly Diagnosed and Relapsed/Refractory AML Patients

Blood (2024) 144 (Supplement 1): 6038.

https://doi.org/10.1182/blood-2024-205250

Published: 2024

Journal Articles

Improved Post-Transplant Outcomes over Time for Older Patients with Acute Lymphoblastic Leukemia in First Complete Remission. a Study from the EBMT Acute Leukemia Working Party

Blood (2024) 144 (Supplement 1): 2185.

https://doi.org/10.1182/blood-2024-206733

Published: 2024

Journal Articles

Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Haploidentical Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

Blood (2024) 144 (Supplement 1): 4944.

https://doi.org/10.1182/blood-2024-207391

Published: 2024

Journal Articles

Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT

Blood (2024) 144 (3): 323–333.

https://doi.org/10.1182/blood.2024024173

Published: 2024

Journal Articles

Results of an Italian Retrospective Clinical Experience on Mediastinal Gray Zone Lymphoma

Blood (2023) 142 (Supplement 1): 4503.

https://doi.org/10.1182/blood-2023-180036

Published: 2023

Journal Articles

Score to Guide Donor Choice in Haploidentical Stem Cell Transplant Using Post-Transplant Cyclophosphamide for Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

Blood (2023) 142 (Supplement 1): 4932.

https://doi.org/10.1182/blood-2023-180075

Published: 2023

Journal Articles

Alternative Donor Transplantation for Severe Aplastic Anemia: A Comparative Study of the Saawp EBMT

Blood (2023) 142 (Supplement 1): 1047.

https://doi.org/10.1182/blood-2023-174724

Published: 2023

Journal Articles

Non-T-Depleted Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Patients with Relapsed/Refractory Secondary Versus De Novo AML: A Study from the ALWP/EBMT

Arnon Nagler, Myriam Labopin, Johanna Tischer, Anna Maria Raiola, Desiree Kunadt, Jan Vydra, Didier Blaise, Simona Sica, Renato Fanin, Julia Winkler, Edouard Forcade, Gwendolyn Van Gorkom, Fabio Ciceri, Mohamad Mohty

Blood (2023) 142 (Supplement 1): 1049.

https://doi.org/10.1182/blood-2023-173636

Published: 2023

Journal Articles

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation from Different Donor Types in Primary Refractory Acute Myeloid Leukemia: A Report from the ALWP of the EBMT

Blood (2022) 140 (Supplement 1): 10613–10615.

https://doi.org/10.1182/blood-2022-165472

Published: 2022

Journal Articles

Graft-Versus-Leukemia Effect Is Independent from Graft-Versus-Host Disease Following Ptcy-Based HLA-Haploidentical Transplantation

Frederic Baron, Myriam Labopin, Johanna Tischer, Anna Maria Raiola, Jan Vydra, Didier Blaise, Patrizia Chiusolo, Friedrich Stölzel, Renato Fanin, Patrice Chevallier, Arnon Nagler, Fabio Ciceri, Mohamad Mohty

Blood (2022) 140 (Supplement 1): 7752–7753.

https://doi.org/10.1182/blood-2022-166023

Published: 2022

Journal Articles

Outcomes of Allogeneic Haematopoietic Stem Cell Transplantation for Therapy-Related Myeloid Neoplasms Following Treatment for Myeloma

Blood (2022) 140 (Supplement 1): 4884–4885.

https://doi.org/10.1182/blood-2022-169326

Published: 2022

Journal Articles

Risk Factors Influencing Transplant Outcomes of Adults with Acute Lymphoblastic Leukemia in First Complete Remission: A Retrospective Analysis from the ALWP of the EBMT

Blood (2022) 140 (Supplement 1): 4870–4871.

https://doi.org/10.1182/blood-2022-166081

Published: 2022

Journal Articles

Overall Survival Improvement Following ALLO-SCT in Patients Older THAN 60 YEARS: A Gruppo Italiano Trapianto DI Midollo Osseo (GITMO) Registry Study

Michele Malagola, Nicola Polverelli, Massimo Martino, Vicky Rubini, Maria Teresa Lupo Stanghellini, Francesca Patriarca, Renato Fanin, Benedetto Bruno, Luisa Giaccone, Danilo Giuseppe Faraci, Giovanni Grillo, Stefania Bramanti, Luca Castagna, Paolo Bernasconi, Anna Amelia Colombo, Marco De Gobbi, Paolo Nicoli, Annalisa Natale, Stella Santarone, Elisabetta Terruzzi, Attilio Olivieri, Ilaria Scortechini, Patrizia Chiusolo, Elisabetta Metafuni, Angelo Michele Carella, Emanuela Merla, Marco Casini, Irene M Cavattoni, Mario Arpinati, Chiara Nozzoli, Ilaria Cutini, Patrizio Mazza, Annamaria Mazzone, Simona Bassi, Francesco Onida, Giorgia Saporiti, Filippo Antonio Canale, Adriana Vacca, Eugenia Piras, Piero Galieni, Sadia Falcioni, Mario Luppi, Giulia Debbia, Anna Paola Iori, Ursula La Rocca, Vincenzo Pavone, Anna Mele, Cristina Skert, Francesca Carobolante, Paola Carluccio, Carlo Borghero, Francesca Elice, Anna Proia, Fulvia Fanelli, Carmine Selleri, Nicoletta Sacchi, Sonia Mammoliti, Elena Oldani, Fabio Ciceri, Francesca Bonifazi, Domenico Russo

Blood (2021) 138 (Supplement 1): 1786.

https://doi.org/10.1182/blood-2021-145970

Published: 2021

Journal Articles

Impact of Comorbidities on Prognosis of Elderly Patients with Acute Myeloid Leukemia Who Receive Hypomethylating Agents

Blood (2021) 138 (Supplement 1): 3373.

https://doi.org/10.1182/blood-2021-149459

Published: 2021

Journal Articles

Post-Transplant Cyclophosphamide in Acute Leukemia Patients Receiving More Than 5/10 HLA-Mismatched Allogeneic Stem Cell Transplantation: A Study on Behalf of the ALWP of the EBMT

Blood (2021) 138 (Supplement 1): 3890.

https://doi.org/10.1182/blood-2021-151087

Published: 2021

Journal Articles

Serological Prevalence of Sars-Cov-2 Infection Among Chronic Myeloid Leukemia Patients Undergoing Tyrosine Kinase Inhibitor Treatment in Italy (COVID-19-HEM Study)

Blood (2020) 136 (Supplement 1): 42.

https://doi.org/10.1182/blood-2020-140032

Published: 2020

Journal Articles

BCR-ABL1 Levels at First Month after TKI Discontinuation Predict Subsequent Maintenance of Treatment-Free Remission: A Study from the "Gruppo Triveneto LMC"

Sara Di Giusto, PhD, Eleonora Toffoletti, MD, Massimiliano Bonifacio, MD, Gianni Binotto, MD, Maria Cristina Miggiano, MD, Elisabetta Calistri, MD, Manuela Stulle, MD, Anna Ermacora, MD, Rossella Stella, MD, Luigi Scaffidi, MD, Fabio D'Amore, MD, Giorgia Scotton, MD, Giovanna De Matteis, PhD, Roberta Bertorelle, PhD, Renato Fanin, MD, Mauro Krampera, MD PhD, Gianpietro Semenzato, MD, Daniela Damiani, MD, Mario Tiribelli, MD

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-135968

Published: 2020

Journal Articles

Intensive Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction for Younger NPM1-Mutated AML Patient: Overcoming the Negative Prognosis of FLT3-ITD Mutation

Paola Minetto, MD PhD, Anna Candoni, Fabio Guolo, MD, Marino Clavio, MD, Maria Elena Zannier, MD, Maurizio Miglino, PhD, Maria Vittoria Dubbini, MD, Anna Sicuranza, PhD, Sara Ciofini, Elisabetta Tedone, Nicoletta Colombo, PhD, Girolamo Pugliese, Filippo Ballerini, MD, Michele Cea, Monica Bocchia, Renato Fanin, MD, Roberto Massimo Lemoli, MD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-142887

Published: 2020

Journal Articles

Generic Versus Branded Imatinib As Frontline Therapy in Chronic-Phase Chronic Myeloid Leukemia Patients in Italy: A Case-Control Study

Massimiliano Bonifacio, MD, Mario Tiribelli, Gianni Binotto, MD, Maria Cristina Miggiano, Marco Basso, Elisabetta Calistri, Luigi Scaffidi, MD, Rossella Stella, Luca Frison, Roberto Sartori, Marco Ruggeri, Gianpietro Semenzato, Renato Fanin, Mauro Krampera

Blood (2019) 134 (Supplement_1): 5909.

https://doi.org/10.1182/blood-2019-131272

Published: 2019

Journal Articles

Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction Is Highly Effective in Young AML Patients with Concomitant NPM1 and FLT3-ITD Mutation Irrespectively of FLT3-ITD Allelic Burden

Blood (2019) 134 (Supplement_1): 3828.

https://doi.org/10.1182/blood-2019-131303

Published: 2019

NARROW

Efficacy of Venetoclax-Based Therapy Followed By Allogeneic Transplantation in Newly Diagnosed and Relapsed/Refractory AML Patients

Improved Post-Transplant Outcomes over Time for Older Patients with Acute Lymphoblastic Leukemia in First Complete Remission. a Study from the EBMT Acute Leukemia Working Party

Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Haploidentical Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT

Results of an Italian Retrospective Clinical Experience on Mediastinal Gray Zone Lymphoma

Score to Guide Donor Choice in Haploidentical Stem Cell Transplant Using Post-Transplant Cyclophosphamide for Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

Alternative Donor Transplantation for Severe Aplastic Anemia: A Comparative Study of the Saawp EBMT

Non-T-Depleted Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Patients with Relapsed/Refractory Secondary Versus De Novo AML: A Study from the ALWP/EBMT

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation from Different Donor Types in Primary Refractory Acute Myeloid Leukemia: A Report from the ALWP of the EBMT

Graft-Versus-Leukemia Effect Is Independent from Graft-Versus-Host Disease Following Ptcy-Based HLA-Haploidentical Transplantation

Outcomes of Allogeneic Haematopoietic Stem Cell Transplantation for Therapy-Related Myeloid Neoplasms Following Treatment for Myeloma

Risk Factors Influencing Transplant Outcomes of Adults with Acute Lymphoblastic Leukemia in First Complete Remission: A Retrospective Analysis from the ALWP of the EBMT

Overall Survival Improvement Following ALLO-SCT in Patients Older THAN 60 YEARS: A Gruppo Italiano Trapianto DI Midollo Osseo (GITMO) Registry Study

Impact of Comorbidities on Prognosis of Elderly Patients with Acute Myeloid Leukemia Who Receive Hypomethylating Agents

Post-Transplant Cyclophosphamide in Acute Leukemia Patients Receiving More Than 5/10 HLA-Mismatched Allogeneic Stem Cell Transplantation: A Study on Behalf of the ALWP of the EBMT

Serological Prevalence of Sars-Cov-2 Infection Among Chronic Myeloid Leukemia Patients Undergoing Tyrosine Kinase Inhibitor Treatment in Italy (COVID-19-HEM Study)

BCR-ABL1 Levels at First Month after TKI Discontinuation Predict Subsequent Maintenance of Treatment-Free Remission: A Study from the "Gruppo Triveneto LMC"

Intensive Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction for Younger NPM1-Mutated AML Patient: Overcoming the Negative Prognosis of FLT3-ITD Mutation

Generic Versus Branded Imatinib As Frontline Therapy in Chronic-Phase Chronic Myeloid Leukemia Patients in Italy: A Case-Control Study

Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction Is Highly Effective in Young AML Patients with Concomitant NPM1 and FLT3-ITD Mutation Irrespectively of FLT3-ITD Allelic Burden

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only